FAT1 expression in different breast lesions and its down-regulation in breast cancer development
FAT1 expression in different breast lesions and its down-regulation in breast cancer development
复制标题
FAT1在不同乳腺病灶中的表达及其在乳腺癌发展中的下调
DOI：
--
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
吕建鑫
中科院分区：
文献类型：
--
作者：
曹欣华;吕建鑫
摘要：背景：乳腺癌是女性最常见的癌症之一，从导管原位癌(DCIS)向浸润性导管癌(IDC)发展的机制尚不完全清楚。FAT1是一种重要的肿瘤调控因子。本研究的目的是检测FAT1在不同乳腺病变中的表达差异，探讨FAT1在乳腺癌发生发展中的作用。材料和方法：应用免疫组织化学方法检测10例乳腺良性病变、5例DCIS、5例IDC和25例浸润性导管癌及伴发导管原位癌(IDC-DCIS)中FAT1蛋白的表达。结果：FAT1钙粘附素在乳腺癌和非肿瘤性乳腺上皮中均有表达。DCIS组FAT1钙粘附素表达与良性组比较差异无统计学意义(P=0.392)。与DCIS组相比，IDC组表达下调。DCIS组和IDC组的阳性率差异有统计学意义(P=0.048)。在IDC-DCIS组中，IDC成分的染色总分显著低于DCIS成分的染色总分(P=0.002)。结论：与DCIS组相比，IDC组中FAT1钙粘附素的表达显著降低，提示其在乳腺癌发生的晚期可能具有抑瘤作用。FAT1钙粘附素可作为一种新的生物标志物应用于临床。
Abstract: Background: Breast cancer is one of the most common cancers in women and the mechanisms under the progression from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) remain incompletely understood. FAT1 is an important tumor regulatory factor. The aim of the study is to detect the possible discrepancy in their expression about FAT1 in different breast lesions and to explore the role of FAT1 in the development of breast cancer. Matients and methods: We used immunohistochemistry to detect protein expression of FAT1 in 10 patients diagnosed with breast benign disease, 5 patients diagnosed with DCIS, 5 patients diagnosed with IDC and 25 patients diagnosed with invasive ductal carcinoma and accompanying ductal carcinoma in situ (IDC-DCIS). Results: FAT1 cadherin was expressed by both neoplastic and non-neoplastic mammary epithelia. FAT1 cadherin expression was not significantly changed in DCIS group in comparison with the benign group (P=0.392). Comparing with the DCIS group, expression in the IDC group appeared to be down-regulated. There was a significant difference for the positive rate between the DCIS and IDC group (P=0.048). In the IDC-DCIS group, the total staining score of the IDC component was significantly lower than the score of DCIS component (P=0.002). Conclusions: FAT1 cadherin expression was found to be significantly decreased in IDC group compared with the DCIS group, which indicated it might have tumor suppressive function in late stage of breast cancer development. FAT1 cadherin can be identified as a new biomarker in clinical practice.